Apatinib and Ginsenoside-Rb1 Synergetically Control the Growth of Hypopharyngeal Carcinoma Cells

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2022 Jan 24

PMID 35069931

Authors

Yanwei Li

Feng He

Yu Zhang

Zhanyu Pan

Affiliations

Soon will be listed here.

Abstract

Background: Apatinib is an anticancer drug known to inhibit the vascular endothelial growth factor receptor-2 (VEGFR-2) through regulating tyrosine kinases. Drug resistance and reduced activity in various cancers is the matter of great concern; thus, researchers opt to use combination of the two or more drugs. So far, its gynergetic anticancer role with a traditional Chinese drug Ginsenoside-Rb1 (G-Rb1) has not been studied in cancers including hypopharyngeal carcinoma.

Objective: The current study is aimed at investigating the anticancer synergetic effects of G-Rb1 and apatinib in hypopharyngeal carcinoma.

Methods: The synergetic effects of both drugs on cell proliferation, wound healing and cell migration, and cell apoptosis were studied in hypopharyngeal carcinoma cells. Furthermore, the xenograft rat model was generated, and tumor inhibition was monitored after treating rats with both drugs as mono- and combination therapy. In addition, protein expression and localization were performed by western blotting and immunofluorescent staining, respectively.

Results: The analyses of the data showed that combination therapy of apatinib and G-Rb1 significantly inhibited the proliferation, migration, and wound healing capability of hypopharyngeal carcinoma cells. Moreover, the glycolysis rate of the cells in the combination therapy (apatinib and G-Rb1) group was significantly decreased as compared to that in the monotherapy group or no treatment group, suggesting that the glycolysis inhibition led to the inhibition of tumor growth. Moreover, the combination therapy on xenograft rats dramatically reduced the tumor size. Furthermore, combination therapy also exhibited an increased count of CD3 and CD4 T cells, as well as the ratio between CD4 and CD8 T cells.

Conclusion: Interestingly, a combination of apatinib and G-Rb1 induced more tumor cell apoptosis and reduced cell proliferation than the individual drug treatment and promote antitumor immunity by enhancing immunomodulatory molecules. Thus, we believe that this study could serve as a valuable platform to assess the synergetic anticancer effects of the herbal as well as synthetic medicines.

Citing Articles

Integrating Chinese medicine into mainstream cancer therapies: a promising future.

Ni B, Xue K, Wang J, Zhou J, Wang L, Wang X Front Oncol. 2024; 14:1412370.

PMID: 38957318 PMC: 11217489. DOI: 10.3389/fonc.2024.1412370.

Advancements and challenges in pharmacokinetic and pharmacodynamic research on the traditional Chinese medicine saponins: a comprehensive review.

Ma Y, Zhao Y, Luo M, Jiang Q, Liu S, Jia Q Front Pharmacol. 2024; 15:1393409.

PMID: 38774213 PMC: 11106373. DOI: 10.3389/fphar.2024.1393409.

Ginsenoside Rb1 Inhibits the Proliferation of Lung Cancer Cells by Inducing the Mitochondrial-mediated Apoptosis Pathway.

Feng L, Liu X, Sun K, Sun Y, Wu W, Chen C Anticancer Agents Med Chem. 2024; 24(12):928-941.

PMID: 38465430 DOI: 10.2174/0118715206299212240304142047.

Ginsenoside Rg3: A Review of its Anticancer Mechanisms and Potential Therapeutic Applications.

Wu L, Bai L, Dai W, Wu Y, Xi P, Zhang J Curr Top Med Chem. 2024; 24(10):869-884.

PMID: 38441023 DOI: 10.2174/0115680266283661240226052054.

Ginsenosides: Allies of gastrointestinal tumor immunotherapy.

Feng Y, Ma F, Wu E, Cheng Z, Wang Z, Yang L Front Pharmacol. 2022; 13:922029.

PMID: 36386161 PMC: 9659574. DOI: 10.3389/fphar.2022.922029.

References

Lu H, Zhou X, Kwok H, Dong M, Liu Z, Poon P . Ginsenoside-Rb1-Mediated Anti-angiogenesis via Regulating PEDF and miR-33a through the Activation of PPAR-γ Pathway. Front Pharmacol. 2017; 8:783. PMC: 5693843. DOI: 10.3389/fphar.2017.00783. View

Varghese B, Sebastian P, Mathew A . Treatment outcome in patients undergoing surgery for carcinoma larynx and hypopharynx: a follow-up study. Acta Otolaryngol. 2009; 129(12):1480-5. DOI: 10.3109/00016480902748520. View

Zhu H, He Y, Ma J, Zhou J, Kong M, Wu C . The dual roles of ginsenosides in improving the anti-tumor efficiency of cyclophosphamide in mammary carcinoma mice. J Ethnopharmacol. 2020; 265:113271. DOI: 10.1016/j.jep.2020.113271. View

Wang Y, Xu X, Tang J, Sun Z, Fu Y, Zhao X . Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α-AKT-mTOR pathway in esophageal squamous cell carcinoma. Cell Biosci. 2021; 11(1):124. PMC: 8261945. DOI: 10.1186/s13578-021-00640-2. View

Yin Q, Chen H, Ma R, Zhang Y, Liu M, Thakur K . Ginsenoside CK induces apoptosis of human cervical cancer HeLa cells by regulating autophagy and endoplasmic reticulum stress. Food Funct. 2021; 12(12):5301-5316. DOI: 10.1039/d1fo00348h. View

Irfan M, Kwak Y, Han C, Hyun S, Rhee M . Adaptogenic effects of on modulation of cardiovascular functions. J Ginseng Res. 2020; 44(4):538-543. PMC: 7322748. DOI: 10.1016/j.jgr.2020.03.001. View

Liao X, Bu Y, Jia Q . Traditional Chinese medicine as supportive care for the management of liver cancer: Past, present, and future. Genes Dis. 2020; 7(3):370-379. PMC: 7452431. DOI: 10.1016/j.gendis.2019.10.016. View

Wang L, Li W, Liu Y, Zhang C, Gao W, Gao L . Clinical study on the safety, efficacy, and prognosis of molecular targeted drug therapy for advanced gastric cancer. Am J Transl Res. 2021; 13(5):4704-4711. PMC: 8205802. View

Zhang J, Yang H, Su H, Song J, Bai Y, Deng L . Berberine and Ginsenoside Rb1 Ameliorate Depression-Like Behavior in Diabetic Rats. Am J Chin Med. 2021; 49(5):1195-1213. DOI: 10.1142/S0192415X21500579. View

10.

Meng M, Ye X, Yang X, Huang G, Wei Z, Ni Y . Apatinib and S-1 combination therapy for the treatment of advanced head and neck neoplasms: Three case reports. J Cancer Res Ther. 2019; 15(2):442-446. DOI: 10.4103/jcrt.JCRT_894_18. View

11.

Scott L . Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers. Drugs. 2018; 78(7):747-758. DOI: 10.1007/s40265-018-0903-9. View

12.

Kim J, Byeon H, Im K, Min H . Effects of ginsenosides on regulatory T cell differentiation. Food Sci Biotechnol. 2018; 27(1):227-232. PMC: 6049740. DOI: 10.1007/s10068-017-0255-3. View

13.

Chen L, Cheng X, Tu W, Qi Z, Li H, Liu F . Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells. Cell Oncol (Dordr). 2019; 42(5):679-690. DOI: 10.1007/s13402-019-00455-x. View

14.

Zhao X, Sun R, Yang X, Liu D, Lei D, Jin T . Chloroquine-enhanced efficacy of cisplatin in the treatment of hypopharyngeal carcinoma in xenograft mice. PLoS One. 2015; 10(4):e0126147. PMC: 4414471. DOI: 10.1371/journal.pone.0126147. View

15.

Lu S, Zhang Y, Li H, Zhang J, Ci Y, Han M . Ginsenoside Rb1 can ameliorate the key inflammatory cytokines TNF-α and IL-6 in a cancer cachexia mouse model. BMC Complement Med Ther. 2020; 20(1):11. PMC: 7076885. DOI: 10.1186/s12906-019-2797-9. View

16.

Zhang H, He S, Spee C, Ishikawa K, Hinton D . SIRT1 mediated inhibition of VEGF/VEGFR2 signaling by Resveratrol and its relevance to choroidal neovascularization. Cytokine. 2015; 76(2):549-552. PMC: 4605850. DOI: 10.1016/j.cyto.2015.06.019. View

17.

Yanwei L, Yinli Y, Pan Z . Traditional Herbal Formula NPC01 Exerts Antiangiogenic Effects through Inhibiting the PI3K/Akt/mTOR Signaling Pathway in Nasopharyngeal Carcinoma Cells. Evid Based Complement Alternat Med. 2018; 2018:5291517. PMC: 5831941. DOI: 10.1155/2018/5291517. View

18.

Sato K, Kubota A, Furukawa M, Kitani Y, Nakayama Y, Nonaka T . Definitive radiotherapy for early-stage hypopharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2014; 272(8):2001-6. DOI: 10.1007/s00405-014-3132-1. View

19.

Wang M, Zeng Q, Li Y, Imani S, Xie D, Li Y . Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model and . J Drug Target. 2020; 28(9):961-969. DOI: 10.1080/1061186X.2020.1764963. View

20.

Lv X, Chen J, Yi T, Lu H, Liu J, Yu D . The efficacy and safety of low-dose Apatinib in the management of stage IV luminal-type breast cancer: a case report and literature review. Anticancer Drugs. 2021; 32(8):773-778. PMC: 8366759. DOI: 10.1097/CAD.0000000000001102. View